Standard BioTools Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Standard BioTools Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-03-31 was $311.25M.
- Standard BioTools Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2019-03-31 was $133.30M, a 355.07% increase year-over-year.
- Standard BioTools Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2018-03-31 was $29.29M.
- Standard BioTools Inc. stock issued during period, value, conversion of convertible securities for fiscal 2024 was $311.25M.
- Standard BioTools Inc. stock issued during period, value, conversion of convertible securities for fiscal 2019 was $133.30M, a 354.06% increase from fiscal 2018.
- Standard BioTools Inc. stock issued during period, value, conversion of convertible securities for fiscal 2018 was $29.36M.
- Standard BioTools Inc. stock issued during period, value, conversion of convertible securities for fiscal 2011 was $184.60M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2024-12-31 | $311.25M 10-K · filed 2025-03-11 | |
| 2024-03-31 | $311.25M 10-Q · filed 2024-11-06 | |
| 2019-12-31 | $133.30M 10-K · filed 2022-03-08 | |
| 2019-03-31 | $133.30M 10-Q · filed 2020-11-09 | |
| 2018-12-31 | $29.36M 10-K · filed 2021-02-25 | |
| 2018-03-31 | $29.29M 10-Q · filed 2019-11-08 | |
| 2011-12-31 | $184.60M 10-K · filed 2014-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |